Evelo Biosciences (NASDAQ: EVLO) is one of 13,326 public companies in the “” industry, but how does it contrast to its peers? We will compare Evelo Biosciences to related businesses based on the strength of its risk, earnings, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Valuation & Earnings
This table compares Evelo Biosciences and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Evelo Biosciences||N/A||-$56.94 million||-3.11|
|Evelo Biosciences Competitors||$7.22 billion||$555.84 million||13.68|
This table compares Evelo Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Evelo Biosciences Competitors||-184.54%||6.33%||1.83%|
Institutional and Insider Ownership
85.1% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 55.9% of shares of all “” companies are owned by institutional investors. 13.4% of shares of all “” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Evelo Biosciences and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Evelo Biosciences Competitors||62176||236305||309317||12821||2.44|
Evelo Biosciences presently has a consensus target price of $22.75, suggesting a potential upside of 163.31%. As a group, “” companies have a potential upside of 24.00%. Given Evelo Biosciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Evelo Biosciences is more favorable than its peers.
Evelo Biosciences peers beat Evelo Biosciences on 7 of the 12 factors compared.
About Evelo Biosciences
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.